Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Duke Cancer Institute | OTHER |
Not provided
Not provided
Not provided
Not provided
The purpose of the study is to explore how feedback of cellular DNA (Deoxyribonucleic Acid) damage, as a marker of exposure to the genotoxic agents of tobacco smoke, promotes cessation.
The study aims to recruit 50 smokers who are not engaged in quitting. The study will involve two in-person visits. During visit 1, participants will complete a baseline survey and have their blood drawn. Approximately two weeks later, in visit 2, smokers will be randomized in a 1:2:2 ratio to one of three arms:
The goal of the analyses is to obtain effect size estimates (direction, confidence intervals) to inform if results align with hypotheses and obtain insights about reactions about the feedback (Aim 1). The study will collect feasibility data from baseline to three months (e.g., percentage who show up to the sessions, attrition).
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Control | Active Comparator | Subjects will review standard health information on the health consequences of smoking. Subjects will have blood drawn but it will not be tested for DNA damage. |
|
| Biomarker feedback | Active Comparator | Subjects will review this standardized health information, plus receive information on DNA damage along with feedback of their DNA damage. Subjects will have blood drawn and the feedback will be presented at Visit 2. |
|
| Biomarker feedback plus | Active Comparator | Subjects will review this standardized health information, information on DNA damage along with feedback of their DNA damage, and will also will see images of their own cells with and without DNA damage. Subjects will have blood drawn and the feedback and images will be presented at Visit 2. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| standard health information | Behavioral | Subjects will review standard health information |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Degree of participant understanding of materials, to be measured by a survey | Study will measure the extent to which the biomarker information was understood, as measured by a survey | week 3 |
| Percentage of subjects who show up to the sessions | Study will collect feasibility data on how many participants come to each visit. | Week 1 |
| Extent to which participants believe the feedback to be accurate | The study will measure the extent to which DNA damage results would be considered accurate using a survey. | week 3 |
| Degree of participant understanding of materials, to be measured by an interview | Study will measure the extent to which the biomarker information was understood, as measured by an interview. | Week 3 |
| Percentage of subjects who show up to the sessions | Study will collect feasibility data on how many participants come to each visit. | Week 3 |
| Extent to which participants believe the feedback to be trustworthy | The study will measure the extent to which DNA damage results would be considered trustworthy using a survey. | Week 3 |
| Extent to which participants believe the feedback to be accurate | The study will measure the extent to which DNA damage results would be considered accurate using an interview. |
| Measure | Description | Time Frame |
|---|---|---|
| Effect size of the changes in coherence between the control and biomarker arm from baseline to three months post-intervention on | Change in coherence, as measured by likert scale | Baseline to 3 months |
| Effect size of the change in risk appraisals between the control and biomarker arm from baseline to three months post-intervention on |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Isaac Lipkus, PhD | Duke University School of Nursing | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Duke University Medical Center | Durham | North Carolina | 27701 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D012907 | Smoking |
| ID | Term |
|---|---|
| D001519 | Behavior |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| standard health information plus info. on DNA damage |
| Behavioral |
Subjects will review standard health information and information on DNA damage |
|
| Subjects will review standard health information and information on DNA damage, plus pictures of their DNA damage | Behavioral | Subjects will review standard health information and information on DNA damage, as well as review pictures of their cells' DNA damage |
|
| Week 3 |
| Extent to which participants believe the feedback to be trustworthy | The study will measure the extent to which DNA damage results would be considered trustworthy using an interview. | Week 3 |
Change in risk appraisals, as measured by a scale |
| Baseline to 3 months |
| Effect size of participant motivation to quit smoking between the control and biomarker arm from baseline to three months post-intervention on | Change in motivation to quit, as measured by a motivation to quit scale | Baseline to 3 months |
| Effect size of plans to quit smoking between the control and biomarker arm from baseline to three months post-intervention on | Change in action planning, as measured by number of participants who have made a plan to quit smoking | Baseline to 3 months |
| Effect size of mean levels of smoking between the control and biomarker arm at three months post-intervention | Mean levels of smoking at 3 months | 3 months |
| Effect size of the number of quit attempts between the control and biomarker arm at three months post-intervention | Number of quit attempts at 3 months | 3 months |
| Effect size of the quit rate between the control and biomarker arm at three months post-intervention | Quit rate at 3 months | 3 months |